Mathur S P, Mathur R S, Young R C
Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston 29425, USA.
Am J Reprod Immunol. 2000 Oct;44(4):222-30. doi: 10.1111/j.8755-8920.2000.440406.x.
To ascertain if cervical epithelial epidermal growth factor receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer.
We tested cervical biopsies obtained from 18 controls, 3 women with cervical intraepithelial neoplasia (CIN) I, 17 women with CIN II and III, and 12 women with cervical cancer for EGF-R using a quantitative immunofluorescent antibody assay. We measured serum IGF-II levels using an enzyme-linked immunosorbent assay in 20 controls, 26 CIN patients, 12 with cervical cancer before therapy, 5 with cervical cancer for < 1 year, and 9 others > 1 year after therapy.
The levels of cervical EGF-R in women with CIN and cervical cancer were significantly higher (P<0.05 for CIN I; P<0.001 for patients with CIN II and III or cervical cancer) than in controls. Women with cervical cancer (P<0.001 vs. controls) or advanced CIN (P = 0.03) had elevated levels of serum IGF-II, while the women with CIN I had levels similar to controls. Women with cervical cancer in the post-therapy period had significantly lower serum IGF-II levels than the women with cervical cancer before therapy (P<0.001).
Cervical epithelial EGF-R and serum IGF-II levels may be used for the diagnosis and prognosis of cervical cancer.
确定宫颈上皮表皮生长因子受体（EGF-R）和血清胰岛素样生长因子II（IGF-II）水平是否为宫颈癌的潜在标志物。
我们采用定量免疫荧光抗体检测法，对18名对照者、3名宫颈上皮内瘤变（CIN）I级女性、17名CIN II级和III级女性以及12名宫颈癌女性的宫颈活检组织进行了EGF-R检测。我们采用酶联免疫吸附测定法，对20名对照者、26名CIN患者、12名治疗前的宫颈癌患者、5名患宫颈癌时间小于1年的患者以及9名治疗后1年以上的其他患者的血清IGF-II水平进行了测定。
CIN患者和宫颈癌患者的宫颈EGF-R水平显著高于对照者（CIN I级，P<0.05；CIN II级和III级患者或宫颈癌患者，P<0.001）。宫颈癌患者（与对照者相比，P<0.001）或高级别CIN患者（P = 0.03）的血清IGF-II水平升高，而CIN I级女性的水平与对照者相似。治疗后宫颈癌患者的血清IGF-II水平显著低于治疗前的宫颈癌患者（P<0.001）。
宫颈上皮EGF-R和血清IGF-II水平可用于宫颈癌的诊断和预后评估。
